Menu
Search
|

Menu

Close
X

Ra Pharmaceuticals Inc RARX.OQ (NASDAQ Stock Exchange Global Market)

11.17 USD
+0.23 (+2.10%)
As of Jul 20
chart
Previous Close 10.94
Open 11.08
Volume 77,671
3m Avg Volume 78,177
Today’s High 11.30
Today’s Low 10.81
52 Week High 17.90
52 Week Low 4.93
Shares Outstanding (mil) 22.61
Market Capitalization (mil) 326.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
2
FY15
1
EPS (USD)
FY18
-0.606
FY17
-2.409
FY16
-1.381
FY15
-0.112
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
3.39
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-60.75
14.61
Return on Equity (TTM)
vs sector
-174.09
16.34

EXECUTIVE LEADERSHIP

Douglas Treco
President, Chief Executive Officer, Co-Founder, Director, Since
Salary: --
Bonus: --
Jeffrey Johnston
Senior Vice President, Chief Medical Officer, Since
Salary: --
Bonus: --
Alonso Ricardo
Senior Vice President of Research & Development, Since
Salary: --
Bonus: --
Kerry Black
Executive Director, Operations, Since
Salary: --
Bonus: --
Edward Mathers
Board Member, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

87 Cambridgepark Dr
CAMBRIDGE   MA   02140-2311

Phone: +1617.4014060

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

SPONSORED STORIES